SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-006722
Filing Date
2024-02-14
Accepted
2024-02-14 16:55:26
Documents
16
Period of Report
2024-02-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39895
2 ex99-1.htm EX-99.1 13100
3 ex99-1_001.jpg GRAPHIC 7668
  Complete submission text file 0001493152-24-006722.txt   237025

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE eltp-20240214.xsd EX-101.SCH 3024
5 XBRL LABEL FILE eltp-20240214_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE eltp-20240214_pre.xml EX-101.PRE 22365
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3401
Mailing Address 165 LUDLOW AVENUE NORTHVALE NJ 07647
Business Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 2017502646
ELITE PHARMACEUTICALS INC /NV/ (Filer) CIK: 0001053369 (see all company filings)

IRS No.: 223542636 | State of Incorp.: NJ | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-15697 | Film No.: 24639910
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)